drugset / Trial / NCT00747487

Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy

NCT00747487

Phase 2 Completed 85 enrolled Santhera Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is meant to assess the effectiveness of idebenone on visual function measures in patients with Leber's Hereditary Optic Neuropathy over a 6 months period.

Timeline

Start
2007-11
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Idebenone Small molecule 900 mg